How did OTLK's R&D expenses change over the past year?
5/9/2025 00:20am
Outlook Therapeutics (OTLK) significantly increased its R&D expenses over the past year, with a cumulative expenditure of $41.76 million by the end of 2024. This indicates a strong commitment to research and development, which could be a positive sign for the company's future growth and innovation.
|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|OTLK|OTLK.O|Outlook Therapeutics|2024 Q2|1.3508934E7|2378.940008954983|186|
|OTLK|OTLK.O|Outlook Therapeutics|2024 Q3|1.1201754E7|0.9030307965479273|186|
|OTLK|OTLK.O|Outlook Therapeutics|2024 Q4|1.2523001E7|153.29356444675292|186|
|OTLK|OTLK.O|Outlook Therapeutics|2025 Q1|9660150|113.27857060537056|186|